FindTrial
Sign In

J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502837-24-00
Acronym
J2A-MC-GZGQ
Enrollment
390
Registered
2023-09-19
Start date
2023-09-25
Completion date
2025-08-07
Last updated
2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight, Type 2 Diabetes

Brief summary

Mean Percent Change from Baseline in Body Weight (from Baseline to Week 72)

Interventions

DRUGORFORGLIPRON
DRUGOrforglipron
DRUGSodium bicarbonate - Placebo to match ly3502970

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Mean Percent Change from Baseline in Body Weight (from Baseline to Week 72)—

Countries

Czechia, Germany, Greece

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026